Description: This series of educational webinars is designed to aid physicians, physician assistants, nurses, pharmacists, pharmacy technicians, students, and other health care professionals, to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety. This webinar will provide an overview of the Office of Health and Constituent Affairs (OHCA), identify opportunities to collaborate and advance FDA public health messages, and promote public involvement with FDA. This webinar will also describe the FDA MedWatch program, demonstrate how to report adverse events to MedWatch, and how to obtain safety information.
- Explain how to utilize FDA’s drug information, medication safety resources, and regulatory guidance, to improve delivery of patient care and optimize outcomes.
- Describe and inform health care providers of recent labeling changes which would impact prescribing and medication management to optimize patient care.
Session Learning Objectives: After completion of this activity, the participant will be able to:
Describe the FDA Office of Health and Constituent Affairs (OHCA).
- List ways to collaborate and be involved in FDA processes.
- Identify adverse events and product problems that should be reported to FDA.
- Demonstrate how to submit a report to the FDA MedWatch Program.
Target Audience: This activity is intended for physicians, physician assistants, nurses, pharmacists, pharmacy technicians, other health care professionals, and students.
1-2 PM– FDA Drug Topics: FDA’s MedWatch Adverse Reporting Program-Opportunities to Collaboratepresented by Steve Morin, R.N., B.S.N., Health Programs Coordinator in FDA’s Office of Health and Constituent Affairs (OHCA).
In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians and physician assistants should claim only the credit commensurate with the extent of their participation in the activity.
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-18-026-L04-P, and ACPE Universal Activity Number JA0002895-0000-18-026-L04-T for 1.00 contact hour(s).
FDA Center for Drug Evaluation and Research designates this activity for 1 contact hour.
Requirements for receiving CE Credit:
Physicians, physician assistants, nurses, pharmacists, pharmacy technicians, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). Final activity evaluations must be completed within two weeks after the activity - no exceptions.
Pharmacy participants: partial credit cannot be awarded, therefore you must attend the entire activity to receive CPE credit. No exceptions. Pharmacists and pharmacy technicians will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.
Important Note regarding completion of evaluations and receiving credit
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the last session of the activity to obtain their CE credit.
FUTURE WEBINAR DATES:
April 10,2018- FDA Drug Topics: An Introduction to Drug Safety Surveillance and the FDA Adverse Event Reporting System.
To learn more about future dates and registration, please visit: www.fda.gov/DDIWebinars.